Ubs Asset Management Americas Inc Atai Life Sciences N.V. Transaction History

Ubs Asset Management Americas Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.27 - $2.28 $11,771 - $21,133	9,269 Added 14.66%	72,480 $93,000
Q4 2022 Feb 14, 2023	BUY	$2.38 - $3.55 $49,127 - $73,279	20,642 Added 48.49%	63,211 $168,000
Q3 2022 Nov 14, 2022	SELL	$3.14 - $4.87 $65,274 - $101,237	-20,788 Reduced 32.81%	42,569 $140,000
Q2 2022 Aug 12, 2022	BUY	$3.03 - $5.32 $191,971 - $337,059	63,357 New	63,357 $230,000

12.4M

77.8K

50.3K

Ticker ATAI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 165,875,008
Market Cap $197M
Description
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

Stay updated on Ubs Asset Management Americas Inc with notifications on news.